Certara Inc
CERT
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.42B
Close$
$7.40
21% downside
Current Fair Value
21% downsideOvervalued by 21% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.42 Billion |
|---|---|
| Enterprise Value | $1.61 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.01 |
| Beta | 1.43 |
| Outstanding Shares | 154,356,779 |
Return
| Return on Equity | -7.08% |
|---|---|
| Return on Assets | -4.89% |
| Return on Invested Capital | 2.25% |
Valuation & Multiples
| P/E Ratio | -20.59 |
|---|---|
| PEG | -0.76 |
| Price to Sales | 4.68 |
| Price to Book Ratio | 1.56 |
| Enterprise Value to Revenue | 3.93 |
| Enterprise Value to EBIT | 55.84 |
| Enterprise Value to Net Income | -24 |
| Total Debt to Enterprise | 0.23 |
| Debt to Equity | 0.38 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$0.10
Average shareholder expectationRevenue Estimate
$98.09 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$0.09
Average shareholder expectationRevenue Estimate
$92.31 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.01%▼ 86.76% |
|---|---|
| Total Invested | $14.30M▼ 98.39% |
| Investors Holding | 8▼ 237.00% |
ESG Score
No data
About Certara Inc
300 employeesCertara optimizes R&D productivity, commercial value and patient outcomes through its unique portfolio of model-informed drug development, regulatory science, and market access solutions. In fact, 90+% of all novel drugs approved by the ...